Cover
Cover - shares | 9 Months Ended | |
Sep. 30, 2022 | Nov. 07, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Sep. 30, 2022 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2022 | |
Current Fiscal Year End Date | --12-31 | |
Entity File Number | 000-56194 | |
Entity Registrant Name | Coeptis Therapeutics, Inc. | |
Entity Central Index Key | 0001819663 | |
Entity Tax Identification Number | 84-3998117 | |
Entity Incorporation, State or Country Code | DE | |
Entity Address, Address Line One | 105 Bradford Rd | |
Entity Address, Address Line Two | Suite 420 | |
Entity Address, City or Town | Wexford | |
Entity Address, State or Province | PA | |
Entity Address, Postal Zip Code | 15090 | |
City Area Code | (724) | |
Local Phone Number | 934-6467 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Elected Not To Use the Extended Transition Period | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 19,516,373 |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
CURRENT ASSETS | ||
Cash | $ 7,370,909 | $ 2,179,558 |
Accounts receivable | 8,075 | 0 |
Inventories | 0 | 0 |
TOTAL CURRENT ASSETS | 7,378,984 | 2,179,558 |
PROPERTY AND EQUIPMENT | ||
Furniture and fixtures | 25,237 | 25,237 |
Less: accumulated depreciation | 12,349 | 11,311 |
Furniture and fixtures, net | 12,888 | 13,926 |
OTHER ASSETS | ||
Co-development options | 3,804,167 | 4,554,167 |
Right of use asset, net of accumulated amortization | 68,541 | 17,925 |
Total other assets | 3,872,708 | 4,572,092 |
TOTAL ASSETS | 11,264,580 | 6,765,576 |
CURRENT LIABILITIES | ||
Accounts payable | 327,873 | 134,092 |
Accrued expenses | 360,176 | 199,126 |
Notes payable, current portion | 3,617,001 | 2,417,000 |
Notes payable, related parties, current portion | 0 | 0 |
Right of use liability, current portion | 9,834 | 14,724 |
TOTAL CURRENT LIABILITIES | 4,314,884 | 2,764,942 |
LONG TERM LIABILITIES | ||
Note payable | 150,000 | 1,650,000 |
Right of use liability, non-current portion | 56,341 | 0 |
TOTAL LONG TERM LIABILITIES | 206,341 | 1,650,000 |
TOTAL LIABILITIES | 4,521,225 | 4,414,942 |
STOCKHOLDERS' EQUITY (DEFICIT) | ||
Series B Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, 8,000 and -0- shares issued and outstanding, respectively | 1 | 1 |
Common stock, $0.0001 par value, 750,000,000 shares authorized, 43,207,163 shares issued and outstanding at September 30, 2022, and 37,082,864 shares issued and 36,754,064 shares outstanding at December 31, 2021 | 4,196 | 3,550 |
Additional paid-in capital | 68,920,525 | 30,144,374 |
Treasury stock, 328,800 shares at cost | 0 | (247,165) |
Accumulated deficit | (62,181,367) | (27,550,126) |
TOTAL STOCKHOLDERS' EQUITY | 6,743,355 | 2,350,634 |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ 11,264,580 | $ 6,765,576 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares | Sep. 30, 2022 | Dec. 31, 2021 |
Preferred stock, par value | $ 0.0001 | |
Preferred stock, shares authorized | 10,000,000 | |
Common stock, par value | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 750,000,000 | 750,000,000 |
Common stock, shares issued | 43,207,163 | 37,082,864 |
Common stock, shares outstanding | 43,207,163 | 36,754,064 |
Treasury Stock, Shares | 328,800 | |
Series B Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Preferred Stock, Shares Issued | 8,000 | 0 |
Preferred Stock, Shares Outstanding | 8,000 | 0 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
SALES | ||||
Total sales | $ 0 | $ 0 | $ 0 | $ 75,000 |
Cost of goods, including inventory obsolescence | 0 | 0 | 0 | 0 |
Gross profit | 0 | 0 | 0 | 75,000 |
COST OF OPERATIONS | ||||
Research and development | 20,887 | 0 | 20,887 | 0 |
General and administrative expenses | 5,488,540 | 6,759,339 | 30,948,831 | 11,077,747 |
Selling and marketing | 2,859 | 0 | 6,911 | 2,918 |
Interest expense | 56,423 | 188,559 | 176,068 | 266,382 |
Total operating expenses | 5,568,709 | 6,947,898 | 31,152,697 | 11,347,048 |
LOSS FROM OPERATIONS | (5,568,709) | (6,947,898) | (31,152,697) | (11,272,048) |
OTHER INCOME (EXPENSE) | ||||
Royalties and licensing fees | (80,000) | 3,543 | (85,000) | (413,124) |
Licensing income | 0 | 1,000,000 | 0 | 1,000,000 |
Other Income | 0 | 0 | 0 | 77,500 |
Other Gain (Loss) *on extinguishment of debt and write down of assets | 0 | (2,000) | (3,393,542) | (2,000) |
TOTAL OTHER INCOME (EXPENSE) | (80,000) | 1,001,543 | (3,478,542) | 662,376 |
LOSS BEFORE INCOME TAXES | (5,648,709) | (5,946,356) | (34,631,239) | (10,609,672) |
PROVISION FOR INCOME TAXES (BENEFIT) | 0 | 0 | 0 | 0 |
NET LOSS | $ (5,648,709) | $ (5,946,356) | $ (34,631,239) | $ (10,609,672) |
LOSS PER SHARE | ||||
Loss per share, basic and fully diluted | $ (0.14) | $ (0.17) | $ (0.90) | $ (0.34) |
Weighted average number of common shares outstanding | 39,944,087 | 34,060,556 | 38,678,939 | 31,054,813 |
Consulting Services [Member] | ||||
SALES | ||||
Total sales | $ 0 | $ 0 | $ 0 | $ 75,000 |
Other Sales [Member] | ||||
SALES | ||||
Total sales | $ 0 | $ 0 | $ 0 | $ 0 |
CONSOLIDATED STATEMENTS OF STOC
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($) | Preferred Stock Series B [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Common Stock Subscribed [Member] | Treasury Stock [Member] | Retained Earnings [Member] | Total |
Beginning balance, value at Dec. 31, 2020 | $ 2,519 | $ 8,954,985 | $ (14,100,846) | $ (5,143,342) | |||
Balance at beginning, shares at Dec. 31, 2020 | 25,178,840 | ||||||
Retroactive application of recapitalization | $ 1 | (298,062) | (298,061) | ||||
Retroactive application of recapitalization, shares | 8,000 | 1,589,400 | |||||
Shares issued for cash | $ 244 | 2,436,256 | 471,000 | 2,907,500 | |||
Shares issued for cash, shares | 2,436,500 | ||||||
Shares issued for services | $ 77 | 769,923 | 770,000 | ||||
Shares issued for services, shares | 770,000 | ||||||
Net income (loss) | (1,950,081) | (1,950,081) | |||||
Ending balance, value at Mar. 31, 2021 | $ 1 | $ 2,839 | 11,863,102 | 471,000 | (16,050,927) | (3,713,987) | |
Balance at ending, shares at Mar. 31, 2021 | 8,000 | 29,974,740 | |||||
Beginning balance, value at Dec. 31, 2020 | $ 2,519 | 8,954,985 | (14,100,846) | (5,143,342) | |||
Balance at beginning, shares at Dec. 31, 2020 | 25,178,840 | ||||||
Net income (loss) | (10,609,672) | ||||||
Ending balance, value at Sep. 30, 2021 | $ 1 | $ 3,317 | 23,902,975 | 1,377,000 | (24,710,518) | 572,774 | |
Balance at ending, shares at Sep. 30, 2021 | 8,000 | 34,750,733 | |||||
Beginning balance, value at Mar. 31, 2021 | $ 1 | $ 2,839 | 11,863,102 | 471,000 | (16,050,927) | (3,713,987) | |
Balance at beginning, shares at Mar. 31, 2021 | 8,000 | 29,974,740 | |||||
Shares issued for cash | $ 128 | 1,922,368 | (388,500) | 1,533,996 | |||
Shares issued for cash, shares | 1,281,664 | ||||||
Shares issued for services | $ 69 | 1,034,931 | 1,035,000 | ||||
Shares issued for services, shares | 690,000 | ||||||
Warrants issued for services | 676,892 | 676,892 | |||||
Shares issued through conversion of debt | $ 69 | 1,040,931 | 1,041,000 | ||||
Shares issued through conversion of debt, Shares | 694,000 | ||||||
Net income (loss) | (2,713,235) | (2,713,235) | |||||
Ending balance, value at Jun. 30, 2021 | $ 1 | $ 3,106 | 16,538,223 | 82,500 | (18,764,162) | (2,140,333) | |
Balance at ending, shares at Jun. 30, 2021 | 8,000 | 32,640,404 | |||||
Shares issued for cash | $ 171 | 2,557,828 | 1,294,500 | 3,852,499 | |||
Shares issued for cash, shares | 1,705,329 | ||||||
Shares issued for services | $ 41 | 607,460 | 607,501 | ||||
Shares issued for services, shares | 405,000 | ||||||
Warrants issued for services | 2,301,879 | 2,301,879 | |||||
Stock based compensation | 1,897,585 | 1,897,585 | |||||
Net income (loss) | (5,946,356) | (5,946,356) | |||||
Ending balance, value at Sep. 30, 2021 | $ 1 | $ 3,317 | 23,902,975 | 1,377,000 | (24,710,518) | 572,774 | |
Balance at ending, shares at Sep. 30, 2021 | 8,000 | 34,750,733 | |||||
Beginning balance, value at Dec. 31, 2021 | $ 1 | $ 3,550 | 30,144,374 | (247,165) | (27,550,126) | 2,350,634 | |
Balance at beginning, shares at Dec. 31, 2021 | 8,000 | 37,082,864 | |||||
Shares issued for cash | $ 42 | 1,265,958 | 1,266,000 | ||||
Shares issued for cash, shares | 421,999 | ||||||
Shares issued for services | $ 118 | 3,539,882 | 3,540,000 | ||||
Shares issued for services, shares | 1,180,000 | ||||||
Retirement of shares | (247,165) | 247,165 | |||||
Retirement of shares, shares | (328,800) | ||||||
Warrants converted to shares | $ 7 | 107,493 | 2,500 | 110,000 | |||
Warrants converted to shares, shares | 73,334 | ||||||
Warrants issued for services | 10,841,695 | 10,841,695 | |||||
Warrants issued for extinguishment of debt | 3,408,559 | 3,408,559 | |||||
Net income (loss) | (19,179,693) | (19,179,693) | |||||
Ending balance, value at Mar. 31, 2022 | $ 1 | $ 3,718 | 49,060,796 | 2,500 | (46,729,821) | 2,337,195 | |
Balance at ending, shares at Mar. 31, 2022 | 8,000 | 38,429,397 | |||||
Beginning balance, value at Dec. 31, 2021 | $ 1 | $ 3,550 | 30,144,374 | (247,165) | (27,550,126) | 2,350,634 | |
Balance at beginning, shares at Dec. 31, 2021 | 8,000 | 37,082,864 | |||||
Net income (loss) | (34,631,239) | ||||||
Ending balance, value at Sep. 30, 2022 | $ 1 | $ 4,196 | 68,920,525 | (62,181,367) | 6,743,355 | ||
Balance at ending, shares at Sep. 30, 2022 | 8,000 | 43,207,163 | |||||
Beginning balance, value at Mar. 31, 2022 | $ 1 | $ 3,718 | 49,060,796 | 2,500 | (46,729,821) | 2,337,195 | |
Balance at beginning, shares at Mar. 31, 2022 | 8,000 | 38,429,397 | |||||
Shares issued for cash | $ 23 | 685,462 | 685,485 | ||||
Shares issued for cash, shares | 228,500 | ||||||
Shares issued for services | $ 6 | 179,994 | 180,000 | ||||
Shares issued for services, shares | 60,000 | ||||||
Warrants converted to shares | $ 30 | 382,471 | 382,500 | ||||
Warrants converted to shares, shares | 295,000 | ||||||
Warrants issued for services | 8,278,691 | 8,278,691 | |||||
Net income (loss) | (9,802,837) | (9,802,837) | |||||
Ending balance, value at Jun. 30, 2022 | $ 1 | $ 3,776 | 58,587,414 | 2,500 | (56,532,658) | 2,061,034 | |
Balance at ending, shares at Jun. 30, 2022 | 8,000 | 39,012,897 | |||||
Shares issued for cash | $ 55 | 1,319,945 | 1,320,000 | ||||
Shares issued for cash, shares | 550,000 | ||||||
Shares issued for services | $ 30 | 899,970 | 900,000 | ||||
Shares issued for services, shares | 300,000 | ||||||
Warrants converted to shares | $ 334 | 4,757,990 | (2,500) | 4,755,824 | |||
Warrants converted to shares, shares | 3,344,266 | ||||||
Warrants issued for services | 3,355,206 | 3,355,206 | |||||
Net income (loss) | (5,648,709) | (5,648,709) | |||||
Ending balance, value at Sep. 30, 2022 | $ 1 | $ 4,196 | $ 68,920,525 | $ (62,181,367) | $ 6,743,355 | ||
Balance at ending, shares at Sep. 30, 2022 | 8,000 | 43,207,163 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
OPERATING ACTIVITIES | ||
Net income (loss) | $ (34,631,239) | $ (10,609,672) |
Adjustments to reconcile net income (loss) to net cash provided (used) by operating activities | ||
Depreciation and amortization | 751,038 | 1,214 |
Forgiveness of debt | 0 | (77,500) |
Shares issued for non-employee services | 4,620,000 | 2,412,500 |
Stock based compensation | 0 | 1,897,585 |
Shares issued for conversion of debt | 0 | 1,041,000 |
Warrants issued for services | 22,475,592 | 2,978,771 |
Warrants issued for extinguishment of debt | 3,408,559 | 0 |
Increase (decrease) in: | ||
Accounts receivable | (8,075) | (4,516) |
Right of use asset/liability | 836 | (988) |
Accounts payable | 193,780 | (340,621) |
Accrued expenses | 161,050 | (578,335) |
Deferred revenue | 0 | (1,000,000) |
NET CASH USED IN OPERATING ACTIVITIES | (3,028,459) | (4,280,561) |
INVESTING ACTIVITIES | ||
Purchase of license right | 0 | (4,804,167) |
NET CASH USED IN INVESTING ACTIVITIES | 0 | (4,804,167) |
FINANCING ACTIVITIES | ||
Proceeds from notes payable | 0 | 4,827,595 |
Repayment of notes payable | (300,000) | (527,905) |
Repayment of notes payable, related parties | 0 | (604,000) |
Cash paid for debt as part of merger/recapitalization | 0 | (298,061) |
Shares issued for cash | 3,271,485 | 6,916,994 |
Shares issued for cash for the conversion warrants | 5,248,324 | 0 |
Cash received for stock subscription | 0 | 1,377,000 |
NET CASH PROVIDED BY FINANCING ACTIVITIES | 8,219,809 | 11,691,623 |
NET INCREASE IN CASH | 5,191,351 | 2,606,897 |
CASH AT BEGINNING OF PERIOD | 2,179,558 | 202,965 |
CASH AT END OF PERIOD | 7,370,909 | 2,809,861 |
SUPPLEMENTAL DISCLOSURES | ||
Interest paid | 0 | 0 |
Taxes paid (refunded) | $ 0 | $ 0 |
DESCRIPTION OF BUSINESS AND BAS
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION | NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Nature of Business The Company is located in Wexford, PA, and engages primarily in the acquisition, development, and commercialization of pharmaceutical products. Merger Pursuant to the Merger Agreement, subject to the terms and conditions set forth therein, (i) prior to the Closing (as defined below), Bull Horn will re-domicile from the British Virgin Islands to the State of Delaware through a statutory re-domestication (the “Domestication”), and (ii) upon the consummation of the transactions contemplated by the Merger Agreement (the “Closing”), Merger Sub will merge with and into Coeptis (the “Merger” and, together with the Domestication and the other transactions contemplated by the Merger Agreement, the “Transactions”), with Coeptis continuing as the surviving corporation in the Merger and a wholly-owned subsidiary of Bull Horn (after the Domestication). Prior to the Merger, all outstanding shares of Coeptis preferred stock will convert or exchange their shares of preferred stock for shares of Coeptis common stock at the applicable ratio in Coeptis organizational documents (the “Preferred Stock Exchange”). In the Merger, (i) all shares of Coeptis common stock issued and outstanding immediately prior to the effective time of the Merger (other than those properly exercising any applicable dissenters rights under Delaware law), but after giving effect to the Preferred Stock Exchange, will be converted into the right to receive a portion of the Merger Consideration (as defined below), (ii) certain issued and outstanding warrants to acquire shares of Coeptis stock (the “Specified Warrants”) will be assumed by Bull Horn and converted into a warrant for shares of Bull Horn common stock with its price and number of shares equitably adjusted based on the conversion of the shares of Coeptis common stock into the Merger Consideration (each, an “Assumed Warrant”), (iii) certain outstanding convertible debt of Coeptis (the “Coeptis Convertible Debt”) will be assumed by Bull Horn and be convertible into common stock of Bull Horn (the “Assumed Convertible Debt”) and (iv) any other outstanding securities with the right to convert into or acquire equity securities of Coeptis or its subsidiaries will be terminated. At the Closing, Bull Horn will change its name to “Coeptis Therapeutics Holdings, Inc.”. The aggregate Merger consideration received by Coeptis security holders from Bull Horn at the Closing will have an aggregate value equal to (the “Merger Consideration”) (i) $ 175,000,000 The Coeptis Convertible Debt, along with (i) certain other outstanding indebtedness of Coeptis as of the date of the Merger Agreement (which together with the Coeptis Convertible Debt, has aggregate outstanding obligations of approximately $ 3.9 Basis of Presentation - Principles of Consolidation – Risks and Uncertainties |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company’s significant accounting policies are described in Note 2 “Summary of Significant Accounting Policies,” in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on March 11, 2022. There have been no material changes to the significant accounting policies during the nine-month period ended September 30, 2022, except for items mentioned below. Use of Estimates Adoption of New Accounting Pronouncements Going Concern 62,181,367 |
LICENSE RIGHT
LICENSE RIGHT | 9 Months Ended |
Sep. 30, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
LICENSE RIGHT | NOTE 3 – LICENSE RIGHT In 2019, the Company entered into an agreement with a foreign entity to market, distribute, and sell the Consensi product (Product) on an exclusive basis within the United States and Puerto Rico. Upon execution of the Agreement the Company paid $1,000,000 to the foreign entity. Milestone payments were due as follows; (1) $1,500,000 upon completion of the CMC Plan as reimbursements of costs incurred by the foreign entity, (2) $1,000,000 was due upon first commercial sale of the Product which occurred in June 2020. Milestones were met and paid as of September 30, 2022. In September of 2021, the Company executed a license termination agreement with the foreign entity to cease all efforts for sales and promotion of the product in the United States and Puerto Rico. The termination included (i) issuance of $ 1,500,000 During the year ended December 31, 2021, the Company and VyGen-Bio, Inc. (“Vy-Gen”) entered into agreements to jointly develop and commercialize two Vy-Gen product candidates, CD38-GEAR-NK and CD38-Diagnostic (the “CD38 Assets”). The Company paid $ 1,750,000 3,250,000 5,000,000 250,000 1,500,000 November 15, 2022 The Company made certain judgements as the basis in determining the accounting treatment of these options. The CD38 Assets represent a platform technology and a diagnostic tool which have multiple applications and uses. Both projects are intended to be used in more than one therapy or diagnostic option. For example, GEAR-NK is a technology which allows for the gene editing of human natural killer cells, so that these cells can no longer bind and be destroyed by targeted monoclonal antibody treatments. The GEAR-NK technology can be modified to work concomitantly with many different monoclonal antibody treatments in which there are currently over 100 approved by the FDA. Anti-CD38 is only the first class of monoclonal antibody treatments being developed under the GEAR-NK platform. Therefore, the pursuit of FDA approval for the use of CD38 assets for at least one indication or medical device approval is at least reasonably expected. Further, as the diagnostic asset may be used as an in vitro technology, it could be classified as a medical device, and therefore toxicity studies would not be a contingency to be resolved before reasonably establishing future value assumptions. In addition, there is perceived value in the CD38 assets, based on publicly disclosed current business deals in cell therapies, the developing market for these innovative technologies, and current interest from third parties in these technologies. The Company may sell or license its right to another party, with the written consent of VyGen Bio, which cannot be unreasonably withheld. Furthermore, the Company believes that any negative results from ongoing development of a single therapy or use, would not result in abandoning the project. Given these considerations, The Company has determined that these options have alternative future use and should be recorded as assets pursuant to ASC 730-10-25-2. Related to the joint development, Coeptis, under the direction of the joint steering committee, is assessing market opportunities, intellectual property protection, and potential regulatory strategies for the CD38 Assets. VyGen Bio is responsible for development activities conducted and overseen by the scientists at Karolinska Institute. The agreement does not currently require additional payments for R&D costs by Coeptis and no additional payments are required upon development or regulatory milestones. |
DEBT
DEBT | 9 Months Ended |
Sep. 30, 2022 | |
Debt Disclosure [Abstract] | |
DEBT | NOTE 4 – DEBT The Company entered into a note payable agreement with an unrelated company with a conversion option. The principal amount of $ 200,000 9 June 15, 2020 200,000 In January 2020, the Company entered into a Senior Secured Note agreement with an unrelated party. The principal amount of $ 500,000 8 plus additional 2% in the event of default February 8, 2021 400,000 1.50 500,000 In January 2020, the Company entered into a Senior Secured Note agreement with a related party stockholder. The principal amount of $ 250,000 8 plus additional 2% in the event of default February 8, 2021 0 0 In January 2020, the Company entered into another Senior Secured Note agreement with a stockholder. The principal amount of $ 250,000 8 February 8, 2021 0 0 In January 2020, the Company entered into a Senior Secured Note agreement with an unrelated party. The principal amount of $ 333,000 8 plus additional 2% in the event of default February 8, 2021 0 333,000 In January 2020, the Company entered into a Senior Secured Note agreement with an unrelated party. The principal amount of $ 167,000 8 plus additional 2% in the event of default February 8, 2021 250,000 1.50 117,000 In September 2020, the Company entered a non-interest bearing, unsecured note agreement with two shareholders for $ 104,000 0 In September 2021, as part of a termination of license agreement with Purple BioTech, the Company issued a convertible note in the principal amount of $ 1,500,000 5 5 Loans under the CARES Act 77,500 77,595 0 77,595 On July 8, 2020, the Company received a loan of $ 150,000 3.75 150,000 Maturities of long-term debt are as follows for the years ended December 31, Schedule of maturities for long-term debt 2022 $ – 2023 – 2024 – 2025 – 2026 – 2027 1,420 Thereafter 148,580 Total long-term debt $ 150,000 |
CAPITAL STRUCTURE
CAPITAL STRUCTURE | 9 Months Ended |
Sep. 30, 2022 | |
Equity [Abstract] | |
CAPITAL STRUCTURE | NOTE 5 – CAPITAL STRUCTURE The total number of shares of stock which the corporation shall have authority to issue is 760,000,000 750,000,000 0.0001 10,000,000 0.0001 Common Stock - 43,207,163 34,750,733 In 2022 and 2021, the Company raised capital by issuance of common stock above the stated par value. The contributed capital recognized as additional paid in capital during the quarter ended September 30, 2022 and 2021 was $ 1,319,945 2,557,828 3,271,365 6,916,452 0 Treasury Stock – 328,800 247,165 328,800 Series A Preferred Stock - 0 Series B Convertible Preferred Stock - 2,000,000 0.0001 All shares of the Series B Preferred Stock shall rank (i) senior to the Corporation’s Common Stock and any other class or series of capital stock of the Corporation hereafter created, (ii) pari passu with any class or series of capital stock of the Corporation hereafter created and specifically ranking, by its terms, on par with the Series B Preferred Stock and (iii) junior to any class or series of capital stock of the Corporation hereafter created specifically ranking, by its terms, senior to the Series B Preferred Stock, in each case as to distribution of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary. The Series B Preferred shall have no liquidation preference over any other class of stock. Each holder of outstanding shares of Series B Preferred Stock shall be entitled to the number of votes equal to equal to one thousand (1,000) Common Shares. Except as provided by law, or by the provisions establishing any other series of Preferred Stock, holders of Series B Preferred Stock and of any other outstanding series of Preferred Stock shall vote together with the holders of Common Stock as a single class. Each holder of shares of Series B Preferred Stock may, at any time and from time to time, convert (an “Optional Conversion”) each of its shares of Series B Preferred Stock into a 1,000 of fully paid and nonassessable shares of Common Stock; provided, however, that any Optional Conversion must involve the issuance of at least 100 shares of Common Stock. In the event of a reverse split, the conversion ratio shall not be changed. However, in the event a forward split shall occur then the conversion ratio shall be modified to be increased by the same ratio as the forward split. The Company has evaluated the Series B Preferred Stock in accordance with ASC 815 and has determined their conversion options were for equity and ASC 815 did not apply as of December 31, 2021. The Company has evaluated the Series B Preferred Stock in accordance with FASB ASC Subtopic 470-20-40 and has determined that there is no beneficial conversion feature that must be accounted for as of December 31, 2021. As of September 30, 2022 and December 31, 2021, there were 8,000 Common Stock Warrants – 500,000 2 5 November 30, 2023 Warrant Holder 1 - 500,000 1 500,000 2 500,000 5 June 1, 2026 As part of the call 2,500 1 1,497,500 Warrant Holder 2 - 200,000 1 100,000 2 100,000 5 July 26, 2026 As part of the call, 5,000 1 195,000 1 75,000 2 25,000 2 100,000 On September 22, 2021, the Company issued a warrant in conjunction with the termination of the license right (see Note 3) with Purple Biotech, granting Purple Biotech the right to purchase 300,000 5 1,897,585 Warrant Holder 3 – 600,000 1 December 20, 2026 As part of the call 300,000 175,000 115,000 1 10,000 1 no Warrant Holder 4 – 300,000 300,000 1 no Warrant Holder 5 – 175,000 200,000 Warrant Holder 6 – 250,000 1.50 January 31, 2024 Warrant Holder 7 - 400,000 1.50 January 31, 2024 Warrant Holder 8 – 775,000 1.50 January 31, 2024 As part of the call 775,000 1.50 no Warrant Holder 9 - 200,000 1.50 January 31, 2024 As part of the call 200,000 1.50 no Warrant Holder 10 - 350,000 1.50 January 31, 2024 As part of the call 53,334 1.50 50,000 1.50 246,666 1.50 no Warrant Holder 11 - 150,000 1 150,000 2 January 31, 2024 170,000 1.50 Warrant Holder 12 - 1,018,050 1.50 January 31, 2024 As part of the call 100,000 1.50 918,050 1.50 no Warrant Holder 13 - 225,000 1.50 January 31, 2024 As part of the call 15,000 1.50 210,000 1.50 no Warrant Holder 14 - 100,000 1 January 31, 2024 100,000 1 no Warrant Holder 15 - 100,000 1.50 January 31, 2024 100,000 1.50 no Warrant Holder 16 - 100,000 1.50 January 31, 2024 25,000 1.50 75,000 1.50 no Warrant Holder 17 - 52,050 1.50 January 31, 2024 52,050 1.50 no Warrant Holder 18 - 250,000 3 March 30, 2024 Warrant Holder 19 - 300,000 1.50 April 1, 2027 300,000 1.50 no The warrants issued since May 28, 2021 and as of September 30, 2022 were valued using the Black-Scholes option pricing model using the following assumptions: 1) exercise price ranging from $1.00 to $5.00 per share, 2) fair value ranging from $4.80 to $6.00 per share, 3) discount rate ranging from 1.15% to 2.31%, 3) dividend rate of 0%, and 4) a term ranging from 2 to 5 years. On April 19, 2022, Coeptis initiated a forced warrant conversation (the call) for certain warrants and on April 20, 2022, for additional warrants. The original expiration for the warrant conversions was set as May 19, 2022, and May 20, 2022. The expiration date was extended and moved to June 30, 2022. A second extension moved the expiration to July 15, 2022, and the third extension moved the expiration date for the warrant conversions to August 1, 2022. The final extension was extended and moved to September 13, 2022. Warrants part of the call that were not exercised by this date expired. Schedule of warrants outstanding Warrant contract # Shares $1.00 $1.50 $2.00 $3.00 $5.00 Coral Investment Partners Warrants 1,000,000 500,000 500,000 Warrant Holder 1 1,500,000 500,000 – 500,000 – 500,000 July 28,2022 (2,500 ) (2,500 ) – – – – 1,497,500 497,500 – 500,000 – 500,000 Warrant Holder 2 400,000 200,000 – 100,000 – 100,000 March 1, 2022 (5,000 ) (5,000 ) – – – – June 27, 2022 (45,000 ) (45,000 ) – – – – June 27, 2022 (225,000 ) (150,000 ) – (75,000 ) – – Expired - September 13, 2022 (25,000 ) – – (25,000 ) – – 100,000 – – – – 100,000 Purple BioTech 300,000 – – – – 300,000 Warrant Holder 3 600,000 600,000 – – – – Transfer to Warrant Holder 4 (300,000 ) (300,000 ) – – – – Transfer to Warrant Holder 5 (175,000 ) (175,000 ) – – – – August 19, 2022 (115,000 ) (115,000 ) – – – – Expired - September 13, 2022 (10,000 ) (10,000 ) – – – – – – Warrant Holder 4 Transfer from Warrant Holder 3 300,000 300,000 – – – – August 19, 2022 (300,000 ) (300,000 ) – – – – – – – – – – Warrant Holder 5 Transfer from Warrant Holder 3 175,000 175,000 – – – – Transfer from Warrant Holder 9 200,000 – 200,000 – – – 375,000 175,000 200,000 – – – Warrant contract # Shares $1.00 $1.50 $2.00 $3.00 $5.00 Warrant Holder 6 250,000 – 250,000 – – – Warrant Holder 7 400,000 – 400,000 – – – Warrant Holder 8 775,000 – 775,000 – – – September 14, 2022 (775,000 ) – (775,000 ) – – – – – – – – – Warrant Holder 9 200,000 – 200,000 – – – Transfer to Warrant Holder 5 (200,000 ) – (200,000 ) – – – – – – – – – Warrant Holder 10 350,000 – 350,000 – – – March 1, 2022 (53,334 ) – (53,334 ) – – – August 19, 2022 (50,000 ) – (50,000 ) – – – September 14, 2022 (246,666 ) – (246,666 ) – – – – – – – – – Warrant Holder 11 300,000 150,000 – 150,000 – – April 14, 2022 170,000 – 170,000 – – – 470,000 150,000 170,000 150,000 – – Warrant Holder 12 1,018,050 – 1,018,050 – – – August 19, 2022 (100,000 ) – (100,000 ) – – – September 14, 2022 (918,050 ) – (918,050 ) – – – – – – – – – Warrant Holder 13 225,000 – 225,000 – – – March 1, 2022 (15,000 ) – (15,000 ) – – – September 14, 2022 (210,000 ) – (210,000 ) – – – – – – – – – Warrant Holder 14 100,000 100,000 – – – – August 19, 2022 (100,000 ) (100,000 ) – – – – – – – – – – Warrant Holder 15 100,000 – 100,000 – – – September 14, 2022 (100,000 ) – (100,000 ) – – – – – – – – – Warrant Holder 16 100,000 – 100,000 – – – June 27, 2022 (25,000 ) – (25,000 ) – – – September 14, 2022 (75,000 ) – (75,000 ) – – – Warrant contract # Shares $1.00 $1.50 $2.00 $3.00 $5.00 Warrant Holder 17 52,050 – 52,050 – – – September 14, 2022 (52,050 ) – (52,050 ) – – – – – – – – – Warrant Holder 18 250,000 – – – 250,000 – Warrant Holder 19 300,000 – 300,000 – – – September 14, 2022 (300,000 ) – (300,000 ) – – – – – – – – – Total warrants outstanding for purchase of shares: 4,642,500 822,500 1,020,000 1,150,000 250,000 1,400,000 |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 9 Months Ended |
Sep. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | NOTE 6 – COMMITMENTS AND CONTINGENCIES Leases 11,250 33,750 Future minimum rental payments required under the lease are as follows: Future minimum rental payments 2022 (remaining) $ 11,250 2023 45,000 2024 14,999 Total minimum lease payments: 71,249 Less amount representing interest (5,074 ) Present value of minimum lease payments: $ 66,175 As of September 30, 2022, the company had recorded a right of use asset of $ 68,541 9,834 56,341 Legal Matters Royalty Obligations - 0 0 Royalty Advances 1,000,000 1,000,000 no Potential Asset Acquisition University of Pittsburgh Option Agreement CAR T License 75,000 75,000 15,000 25,000 |
401(k) PROFIT-SHARING PLAN
401(k) PROFIT-SHARING PLAN | 9 Months Ended |
Sep. 30, 2022 | |
Retirement Benefits [Abstract] | |
401(k) PROFIT-SHARING PLAN | NOTE 7 – 401(k) PROFIT-SHARING PLAN The Company sponsors a qualified profit-sharing plan with a 401(k) feature that covers all eligible employees. Participation in the 401(k) feature of the plan is voluntary. Participating employees may defer up to 100% of their compensation up to the maximum prescribed by the Internal Revenue Code. The plan permits for employee elective deferrals but has no contribution requirements for the Company. During the nine months ended September 30, 2022 and 2021, no |
INCOME TAXES
INCOME TAXES | 9 Months Ended |
Sep. 30, 2022 | |
Income Tax Disclosure [Abstract] | |
INCOME TAXES | NOTE 8 – INCOME TAXES For the nine months ended September 30, 2022 and 2021, respectively, no |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 9 Months Ended |
Sep. 30, 2022 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | NOTE 9 – SUBSEQUENT EVENTS 1. On October 6, 2022, Coeptis entered into an annual service agreement with ACF Equity Research Ltd. to provide independent equity valuation research. 2. On October 26, 2022, the Company held a special meeting of its stockholders in connection with its previously announced business combination with Bull Horn Holdings Corp. (“Bull Horn”) pursuant to that certain Agreement and Plan of Merger, dated as of April 18, 2022 (the “Merger Agreement”). There were sufficient votes to approve the merger and business combination. On October 28, 2022, the Company completed the merger and business combination with Bull Horn Holdings Corp.. In connection with the business combination, the combined company was renamed “Coeptis Therapeutics Holdings, Inc.” and its public shares and warrants commenced trading on the Nasdaq Global Market under the ticker symbols “COEP” and “COEPW,” respectively, on October 31, 2022. |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
Use of Estimates | Use of Estimates |
Adoption of New Accounting Pronouncements | Adoption of New Accounting Pronouncements |
Going Concern | Going Concern 62,181,367 |
DEBT (Tables)
DEBT (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Debt Disclosure [Abstract] | |
Schedule of maturities for long-term debt | Schedule of maturities for long-term debt 2022 $ – 2023 – 2024 – 2025 – 2026 – 2027 1,420 Thereafter 148,580 Total long-term debt $ 150,000 |
CAPITAL STRUCTURE (Tables)
CAPITAL STRUCTURE (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Equity [Abstract] | |
Schedule of warrants outstanding | Schedule of warrants outstanding Warrant contract # Shares $1.00 $1.50 $2.00 $3.00 $5.00 Coral Investment Partners Warrants 1,000,000 500,000 500,000 Warrant Holder 1 1,500,000 500,000 – 500,000 – 500,000 July 28,2022 (2,500 ) (2,500 ) – – – – 1,497,500 497,500 – 500,000 – 500,000 Warrant Holder 2 400,000 200,000 – 100,000 – 100,000 March 1, 2022 (5,000 ) (5,000 ) – – – – June 27, 2022 (45,000 ) (45,000 ) – – – – June 27, 2022 (225,000 ) (150,000 ) – (75,000 ) – – Expired - September 13, 2022 (25,000 ) – – (25,000 ) – – 100,000 – – – – 100,000 Purple BioTech 300,000 – – – – 300,000 Warrant Holder 3 600,000 600,000 – – – – Transfer to Warrant Holder 4 (300,000 ) (300,000 ) – – – – Transfer to Warrant Holder 5 (175,000 ) (175,000 ) – – – – August 19, 2022 (115,000 ) (115,000 ) – – – – Expired - September 13, 2022 (10,000 ) (10,000 ) – – – – – – Warrant Holder 4 Transfer from Warrant Holder 3 300,000 300,000 – – – – August 19, 2022 (300,000 ) (300,000 ) – – – – – – – – – – Warrant Holder 5 Transfer from Warrant Holder 3 175,000 175,000 – – – – Transfer from Warrant Holder 9 200,000 – 200,000 – – – 375,000 175,000 200,000 – – – Warrant contract # Shares $1.00 $1.50 $2.00 $3.00 $5.00 Warrant Holder 6 250,000 – 250,000 – – – Warrant Holder 7 400,000 – 400,000 – – – Warrant Holder 8 775,000 – 775,000 – – – September 14, 2022 (775,000 ) – (775,000 ) – – – – – – – – – Warrant Holder 9 200,000 – 200,000 – – – Transfer to Warrant Holder 5 (200,000 ) – (200,000 ) – – – – – – – – – Warrant Holder 10 350,000 – 350,000 – – – March 1, 2022 (53,334 ) – (53,334 ) – – – August 19, 2022 (50,000 ) – (50,000 ) – – – September 14, 2022 (246,666 ) – (246,666 ) – – – – – – – – – Warrant Holder 11 300,000 150,000 – 150,000 – – April 14, 2022 170,000 – 170,000 – – – 470,000 150,000 170,000 150,000 – – Warrant Holder 12 1,018,050 – 1,018,050 – – – August 19, 2022 (100,000 ) – (100,000 ) – – – September 14, 2022 (918,050 ) – (918,050 ) – – – – – – – – – Warrant Holder 13 225,000 – 225,000 – – – March 1, 2022 (15,000 ) – (15,000 ) – – – September 14, 2022 (210,000 ) – (210,000 ) – – – – – – – – – Warrant Holder 14 100,000 100,000 – – – – August 19, 2022 (100,000 ) (100,000 ) – – – – – – – – – – Warrant Holder 15 100,000 – 100,000 – – – September 14, 2022 (100,000 ) – (100,000 ) – – – – – – – – – Warrant Holder 16 100,000 – 100,000 – – – June 27, 2022 (25,000 ) – (25,000 ) – – – September 14, 2022 (75,000 ) – (75,000 ) – – – Warrant contract # Shares $1.00 $1.50 $2.00 $3.00 $5.00 Warrant Holder 17 52,050 – 52,050 – – – September 14, 2022 (52,050 ) – (52,050 ) – – – – – – – – – Warrant Holder 18 250,000 – – – 250,000 – Warrant Holder 19 300,000 – 300,000 – – – September 14, 2022 (300,000 ) – (300,000 ) – – – – – – – – – Total warrants outstanding for purchase of shares: 4,642,500 822,500 1,020,000 1,150,000 250,000 1,400,000 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Future minimum rental payments | Future minimum rental payments 2022 (remaining) $ 11,250 2023 45,000 2024 14,999 Total minimum lease payments: 71,249 Less amount representing interest (5,074 ) Present value of minimum lease payments: $ 66,175 |
DESCRIPTION OF BUSINESS AND B_2
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) | 9 Months Ended |
Sep. 30, 2022 USD ($) | |
Accounting Policies [Abstract] | |
Consideration received | $ 175,000,000 |
Convertible debt | $ 3,900,000 |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Accounting Policies [Abstract] | ||
Retained Earnings (Accumulated Deficit) | $ 62,181,367 | $ 27,550,126 |
LICENSE RIGHT (Details Narrativ
LICENSE RIGHT (Details Narrative) - USD ($) | 1 Months Ended | 9 Months Ended | 12 Months Ended | |
Mar. 31, 2022 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Finite-Lived Intangible Assets [Line Items] | ||||
Issuance of convertible debt | $ 3,900,000 | |||
Repayments of Notes Payable | $ 250,000 | 300,000 | $ 527,905 | |
CD38 Assets [Member] | ||||
Finite-Lived Intangible Assets [Line Items] | ||||
Notes Issued | $ 3,250,000 | |||
Notes Payable, Noncurrent | $ 1,500,000 | |||
Debt Instrument, Maturity Date | Nov. 15, 2022 | |||
CD38 Assets [Member] | ||||
Finite-Lived Intangible Assets [Line Items] | ||||
Payments to Acquire Intangible Assets | $ 1,750,000 | |||
Capitalized Contract Cost, Gross | $ 5,000,000 | |||
Consensi [Member] | ||||
Finite-Lived Intangible Assets [Line Items] | ||||
Issuance of convertible debt | $ 1,500,000 |
DEBT (Details)
DEBT (Details) | Dec. 31, 2021 USD ($) |
Debt Disclosure [Abstract] | |
2022 | $ 0 |
2023 | 0 |
2024 | 0 |
2025 | 0 |
2026 | 0 |
2027 | 1,420 |
Thereafter | 148,580 |
Total long-term debt | $ 150,000 |
DEBT (Details Narrative)
DEBT (Details Narrative) - USD ($) | 1 Months Ended | 2 Months Ended | 4 Months Ended | 6 Months Ended | 9 Months Ended | ||||
Jan. 31, 2020 | Feb. 28, 2021 | May 06, 2020 | Jul. 08, 2020 | Sep. 30, 2022 | Apr. 14, 2022 | Sep. 30, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | |
License Agreement [Member] | Purple Bio Tech [Member] | |||||||||
Debt Instrument [Line Items] | |||||||||
Principal amount | $ 1,500,000 | ||||||||
Debt Instrument, Interest Rate During Period | 5% | ||||||||
Debt Instrument, Convertible, Conversion Price | $ 5 | ||||||||
Note Payable 1 [Member] | |||||||||
Debt Instrument [Line Items] | |||||||||
Principal amount | $ 200,000 | ||||||||
Debt stated interest rate | 9% | ||||||||
Debt maturity date | Jun. 15, 2020 | ||||||||
Note payable | $ 200,000 | ||||||||
Note Payable 2 [Member] | |||||||||
Debt Instrument [Line Items] | |||||||||
Principal amount | $ 500,000 | ||||||||
Debt stated interest rate | 8% | ||||||||
Debt maturity date | Feb. 08, 2021 | ||||||||
Note payable | $ 500,000 | ||||||||
Debt Instrument, Interest Rate Terms | plus additional 2% in the event of default | ||||||||
Note Payable 2 [Member] | Debt Extension [Member] | Warrant [Member] | |||||||||
Debt Instrument [Line Items] | |||||||||
exchange of warrants | 400,000 | ||||||||
Warrant exercise price | $ 1.50 | ||||||||
Note Payable 3 [Member] | |||||||||
Debt Instrument [Line Items] | |||||||||
Principal amount | $ 250,000 | ||||||||
Debt stated interest rate | 8% | ||||||||
Debt maturity date | Feb. 08, 2021 | ||||||||
Note payable | 0 | $ 0 | |||||||
Debt Instrument, Interest Rate Terms | plus additional 2% in the event of default | ||||||||
Note Payable 4 [Member] | |||||||||
Debt Instrument [Line Items] | |||||||||
Principal amount | $ 250,000 | ||||||||
Debt stated interest rate | 8% | ||||||||
Debt maturity date | Feb. 08, 2021 | ||||||||
Note payable | 0 | 0 | |||||||
Note Payable 5 [Member] | |||||||||
Debt Instrument [Line Items] | |||||||||
Principal amount | $ 333,000 | ||||||||
Debt stated interest rate | 8% | ||||||||
Debt maturity date | Feb. 08, 2021 | ||||||||
Note payable | 0 | 333,000 | |||||||
Debt Instrument, Interest Rate Terms | plus additional 2% in the event of default | ||||||||
Note Payable 6 [Member] | |||||||||
Debt Instrument [Line Items] | |||||||||
Principal amount | $ 167,000 | ||||||||
Debt stated interest rate | 8% | ||||||||
Debt maturity date | Feb. 08, 2021 | ||||||||
Note payable | 117,000 | ||||||||
Debt Instrument, Interest Rate Terms | plus additional 2% in the event of default | ||||||||
Note Payable 6 [Member] | Debt Extension [Member] | |||||||||
Debt Instrument [Line Items] | |||||||||
exchange of warrants | 250,000 | ||||||||
Warrant exercise price | $ 1.50 | ||||||||
Note Payable 7 [Member] | |||||||||
Debt Instrument [Line Items] | |||||||||
Principal amount | $ 104,000 | ||||||||
Note payable | 0 | 0 | |||||||
PPP Loan [Member] | |||||||||
Debt Instrument [Line Items] | |||||||||
Note payable | 0 | 77,595 | |||||||
Proceeds from loan | $ 77,595 | $ 77,500 | |||||||
EIDL Loan [Member] | |||||||||
Debt Instrument [Line Items] | |||||||||
Debt stated interest rate | 3.75% | ||||||||
Note payable | $ 150,000 | $ 150,000 | |||||||
Proceeds from loan | $ 150,000 |
CAPITAL STRUCTURE (Details)
CAPITAL STRUCTURE (Details) - shares | Sep. 30, 2022 | Sep. 14, 2022 | Sep. 13, 2022 | Aug. 19, 2022 | Jul. 28, 2022 | Jun. 28, 2022 | Jun. 27, 2022 | Apr. 14, 2022 | Mar. 02, 2022 | May 28, 2021 |
Coral Investment Partners Warrants [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 1,000,000 | |||||||||
Coral Investment Partners Warrants [Member] | Exercise price $2.00 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 500,000 | |||||||||
Coral Investment Partners Warrants [Member] | Exercise Price $5.00 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 500,000 | |||||||||
Warrant Holder 1 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 1,497,500 | |||||||||
Class of Warrant or Right, Outstanding Gross | 1,500,000 | (2,500) | ||||||||
Warrant Holder 1 [Member] | Exercise price $2.00 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 500,000 | 500,000 | ||||||||
Class of Warrant or Right, Outstanding Gross | 500,000 | |||||||||
Warrant Holder 1 [Member] | Exercise Price $5.00 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 500,000 | 500,000 | ||||||||
Class of Warrant or Right, Outstanding Gross | 500,000 | |||||||||
Warrant Holder 1 [Member] | Exercise Price $1.00 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 497,500 | (2,500) | 500,000 | |||||||
Class of Warrant or Right, Outstanding Gross | 500,000 | |||||||||
Warrant Holder 2 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 100,000 | |||||||||
Class of Warrant or Right, Outstanding Gross | 400,000 | (25,000) | (225,000) | (45,000) | (5,000) | |||||
Warrant Holder 2 [Member] | Exercise price $2.00 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | 100,000 | (25,000) | (75,000) | |||||||
Warrant Holder 2 [Member] | Exercise Price $5.00 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 100,000 | |||||||||
Class of Warrant or Right, Outstanding Gross | 100,000 | |||||||||
Warrant Holder 2 [Member] | Exercise Price $1.00 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | 200,000 | (150,000) | (45,000) | (5,000) | ||||||
Purple Bio Tech Warrant [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 300,000 | |||||||||
Purple Bio Tech Warrant [Member] | Exercise Price $5.00 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 300,000 | |||||||||
Warrant Holder 3 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||
Class of Warrant or Right, Outstanding Gross | 600,000 | (10,000) | (115,000) | |||||||
Warrant Holder 3 [Member] | Transfer To Warrant Holder 4 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | (300,000) | |||||||||
Warrant Holder 3 [Member] | Transfer To Warrant Holder 5 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | (175,000) | |||||||||
Warrant Holder 3 [Member] | Exercise Price $1.00 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | 600,000 | (10,000) | (115,000) | |||||||
Warrant Holder 3 [Member] | Exercise Price $1.00 [Member] | Transfer To Warrant Holder 4 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | (300,000) | |||||||||
Warrant Holder 3 [Member] | Exercise Price $1.00 [Member] | Transfer To Warrant Holder 5 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | (175,000) | |||||||||
Warrant Holder 4 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||
Class of Warrant or Right, Outstanding Gross | (300,000) | |||||||||
Warrant Holder 4 [Member] | Transfer From Warrant Holder 3 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | 300,000 | |||||||||
Warrant Holder 4 [Member] | Exercise Price $1.00 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | (300,000) | |||||||||
Warrant Holder 4 [Member] | Exercise Price $1.00 [Member] | Transfer From Warrant Holder 3 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | 300,000 | |||||||||
Warrant Holder 5 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 375,000 | |||||||||
Warrant Holder 5 [Member] | Transfer From Warrant Holder 3 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | 175,000 | |||||||||
Warrant Holder 5 [Member] | Transfer From Warrant Holder 9 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | 200,000 | |||||||||
Warrant Holder 5 [Member] | Exercise Price $1.00 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 175,000 | |||||||||
Warrant Holder 5 [Member] | Exercise Price $1.00 [Member] | Transfer From Warrant Holder 3 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | 175,000 | |||||||||
Warrant Holder 5 [Member] | Exercise Price $1.50 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 200,000 | |||||||||
Class of Warrant or Right, Outstanding Gross | 200,000 | |||||||||
Warrant Holder 6 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 250,000 | |||||||||
Warrant Holder 6 [Member] | Exercise Price $1.50 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 250,000 | |||||||||
Warrant Holder 7 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 400,000 | |||||||||
Warrant Holder 7 [Member] | Exercise Price $1.50 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 400,000 | |||||||||
Warrant Holder 8 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||
Class of Warrant or Right, Outstanding Gross | 775,000 | (775,000) | ||||||||
Warrant Holder 8 [Member] | Exercise Price $1.50 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | 775,000 | (775,000) | ||||||||
Warrant Holder 9 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||
Class of Warrant or Right, Outstanding Gross | 200,000 | |||||||||
Warrant Holder 9 [Member] | Transfer To Warrant Holder 5 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | (200,000) | |||||||||
Warrant Holder 9 [Member] | Exercise Price $1.50 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | 200,000 | |||||||||
Warrant Holder 9 [Member] | Exercise Price $1.50 [Member] | Transfer From Warrant Holder 5 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | (200,000) | |||||||||
Warrant Holder 10 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||
Class of Warrant or Right, Outstanding Gross | 350,000 | (246,666) | (50,000) | (53,334) | ||||||
Warrant Holder 10 [Member] | Exercise Price $1.50 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | 350,000 | (246,666) | (50,000) | (53,334) | ||||||
Warrant Holder 11 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 470,000 | |||||||||
Class of Warrant or Right, Outstanding Gross | 300,000 | 170,000 | ||||||||
Warrant Holder 11 [Member] | Exercise price $2.00 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 150,000 | |||||||||
Class of Warrant or Right, Outstanding Gross | 150,000 | |||||||||
Warrant Holder 11 [Member] | Exercise Price $1.00 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 150,000 | |||||||||
Class of Warrant or Right, Outstanding Gross | 150,000 | |||||||||
Warrant Holder 11 [Member] | Exercise Price $1.50 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 170,000 | |||||||||
Class of Warrant or Right, Outstanding Gross | 170,000 | |||||||||
Warrant Holder 12 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||
Class of Warrant or Right, Outstanding Gross | 1,018,050 | (918,050) | (100,000) | |||||||
Warrant Holder 12 [Member] | Exercise Price $1.50 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | 1,018,050 | (918,050) | (100,000) | |||||||
Warrant Holder 13 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||
Class of Warrant or Right, Outstanding Gross | 225,000 | (210,000) | (15,000) | |||||||
Warrant Holder 13 [Member] | Exercise Price $1.50 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | 225,000 | (210,000) | (15,000) | |||||||
Warrant Holder 14 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||
Class of Warrant or Right, Outstanding Gross | 100,000 | (100,000) | ||||||||
Warrant Holder 14 [Member] | Exercise Price $1.00 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | 100,000 | (100,000) | ||||||||
Warrant Holder 15 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||
Class of Warrant or Right, Outstanding Gross | 100,000 | (100,000) | ||||||||
Warrant Holder 15 [Member] | Exercise Price $1.50 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | 100,000 | (100,000) | ||||||||
Warrant Holder 16 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||
Class of Warrant or Right, Outstanding Gross | 100,000 | (75,000) | (25,000) | |||||||
Warrant Holder 16 [Member] | Exercise Price $1.50 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | 100,000 | (75,000) | (25,000) | |||||||
Warrant Holder 17 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||
Class of Warrant or Right, Outstanding Gross | 52,050 | (52,050) | ||||||||
Warrant Holder 17 [Member] | Exercise Price $1.50 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | 52,050 | (52,050) | ||||||||
Warrant Holder 18 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 250,000 | |||||||||
Warrant Holder 18 [Member] | Exercise Price $3.00 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 250,000 | |||||||||
Warrant Holder 19 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 0 | |||||||||
Class of Warrant or Right, Outstanding Gross | 300,000 | (300,000) | ||||||||
Warrant Holder 19 [Member] | Exercise Price $1.50 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding Gross | 300,000 | (300,000) | ||||||||
Warrant [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 4,642,500 | |||||||||
Warrant [Member] | Exercise price $2.00 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 1,150,000 | |||||||||
Warrant [Member] | Exercise Price $5.00 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 1,400,000 | |||||||||
Warrant [Member] | Exercise Price $1.00 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 822,500 | |||||||||
Warrant [Member] | Exercise Price $1.50 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 1,020,000 | |||||||||
Warrant [Member] | Exercise Price $3.00 [Member] | ||||||||||
Class of Stock [Line Items] | ||||||||||
Class of Warrant or Right, Outstanding | 250,000 |
CAPITAL STRUCTURE (Details Narr
CAPITAL STRUCTURE (Details Narrative) - USD ($) | 1 Months Ended | 2 Months Ended | 3 Months Ended | 9 Months Ended | ||||||||||||||||||||
Sep. 06, 2022 | Jul. 13, 2022 | Nov. 23, 2020 | Dec. 20, 2021 | Feb. 28, 2021 | Feb. 18, 2022 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 14, 2022 | Sep. 13, 2022 | Aug. 19, 2022 | Jul. 28, 2022 | Jun. 27, 2022 | Apr. 14, 2022 | Mar. 30, 2022 | Mar. 02, 2022 | Jan. 28, 2022 | Dec. 31, 2021 | Dec. 28, 2021 | Sep. 22, 2021 | Jul. 30, 2021 | May 28, 2021 | |
Class of Stock [Line Items] | ||||||||||||||||||||||||
Number of share issued | 760,000,000 | |||||||||||||||||||||||
Common stock, shares authorized | 750,000,000 | 750,000,000 | 750,000,000 | |||||||||||||||||||||
Common stock, par value | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||||||||||||||||
Preferred stock, shares authorized | 10,000,000 | 10,000,000 | ||||||||||||||||||||||
Preferred stock, par value | $ 0.0001 | $ 0.0001 | ||||||||||||||||||||||
Common stock, shares issued | 43,207,163 | 43,207,163 | 37,082,864 | |||||||||||||||||||||
Common stock, shares outstanding | 43,207,163 | 43,207,163 | 36,754,064 | |||||||||||||||||||||
Additional paid in capital | $ 1,319,945 | $ 2,557,828 | $ 3,271,365 | $ 6,916,452 | ||||||||||||||||||||
Capital distributions | 0 | $ 0 | 0 | $ 0 | ||||||||||||||||||||
Common stock repurchased shares | 328,800 | |||||||||||||||||||||||
Treasury stock | $ 0 | $ 0 | $ 247,165 | $ 247,165 | ||||||||||||||||||||
Treasury Stock retired | 328,800 | |||||||||||||||||||||||
Services To Be Provided [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 1 | |||||||||||||||||||||||
Warrant expiration date | Dec. 20, 2026 | |||||||||||||||||||||||
Common Stock [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Common stock, shares issued | 43,207,163 | 34,750,733 | 43,207,163 | 34,750,733 | ||||||||||||||||||||
Common stock, shares outstanding | 43,207,163 | 34,750,733 | 43,207,163 | 34,750,733 | ||||||||||||||||||||
Series A Preferred Stock [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Preferred stock, shares outstanding | 0 | 0 | ||||||||||||||||||||||
Series B Convertible Preferred Stock [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Preferred stock, shares authorized | 2,000,000 | 2,000,000 | ||||||||||||||||||||||
Preferred stock, par value | $ 0.0001 | $ 0.0001 | ||||||||||||||||||||||
Series B Preferred Stock [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Preferred stock, shares authorized | 10,000,000 | 10,000,000 | 10,000,000 | |||||||||||||||||||||
Preferred stock, par value | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||||||||||||||||
Preferred stock, shares outstanding | 8,000 | 8,000 | 0 | |||||||||||||||||||||
Coral Investment Partners Warrants [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 1,000,000 | 1,000,000 | ||||||||||||||||||||||
Class of Warrant or Right, Date from which Warrants or Rights Exercisable | Nov. 30, 2023 | |||||||||||||||||||||||
Coral Investment Partners Warrants [Member] | Exercise price $2.00 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 500,000 | 500,000 | ||||||||||||||||||||||
Coral Investment Partners Warrants [Member] | Exercise Price $5.00 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 500,000 | 500,000 | ||||||||||||||||||||||
Coral Investment Partners Warrants [Member] | Warrant Class A [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 500,000 | |||||||||||||||||||||||
Coral Investment Partners Warrants [Member] | Warrant Class A [Member] | Exercise price $2.00 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 2 | |||||||||||||||||||||||
Coral Investment Partners Warrants [Member] | Warrant Class B [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 500,000 | |||||||||||||||||||||||
Coral Investment Partners Warrants [Member] | Warrant Class B [Member] | Exercise Price $5.00 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 5 | |||||||||||||||||||||||
Warrant Holder 1 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 1,497,500 | 1,497,500 | ||||||||||||||||||||||
Warrant expiration date | Jun. 01, 2026 | |||||||||||||||||||||||
Warrant Holder 1 [Member] | Exercise price $2.00 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 500,000 | 500,000 | 500,000 | |||||||||||||||||||||
Warrant exercise price | $ 2 | |||||||||||||||||||||||
Warrant Holder 1 [Member] | Exercise Price $5.00 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 500,000 | 500,000 | 500,000 | |||||||||||||||||||||
Warrant exercise price | $ 5 | |||||||||||||||||||||||
Warrant Holder 1 [Member] | Exercise Price $1.00 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 497,500 | 497,500 | (2,500) | 500,000 | ||||||||||||||||||||
Warrant exercise price | $ 1 | $ 1 | ||||||||||||||||||||||
Warrants outstanding | 2,500 | |||||||||||||||||||||||
Warrant Holder 2 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 100,000 | 100,000 | ||||||||||||||||||||||
Warrant Holder 2 [Member] | Professional Services 2 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant expiration date | Jul. 26, 2026 | |||||||||||||||||||||||
Warrant Holder 2 [Member] | Termination Of License Right [Member] | Purple Bio Tech [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 5 | |||||||||||||||||||||||
Warrants outstanding | 300,000 | |||||||||||||||||||||||
Share-based Payment Arrangement, Expense | $ 1,897,585 | |||||||||||||||||||||||
Warrant Holder 2 [Member] | Exercise Price $5.00 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 100,000 | 100,000 | ||||||||||||||||||||||
Warrant Holder 2 [Member] | Warrant 1 [Member] | Professional Services 2 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 1 | |||||||||||||||||||||||
Warrants outstanding | 200,000 | |||||||||||||||||||||||
Warrant Holder 2 [Member] | Warrant 2 [Member] | Professional Services 2 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 2 | |||||||||||||||||||||||
Warrants outstanding | 100,000 | |||||||||||||||||||||||
Warrant Holder 2 [Member] | Warrant 3 [Member] | Professional Services 2 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 5 | |||||||||||||||||||||||
Warrants outstanding | 100,000 | |||||||||||||||||||||||
Warrant Holder 2 [Member] | Warrant 4 [Member] | Professional Services 2 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 1 | |||||||||||||||||||||||
Warrants outstanding | 5,000 | |||||||||||||||||||||||
Warrant Holder 2 [Member] | Warrant 5 [Member] | Professional Services 2 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 1 | |||||||||||||||||||||||
Warrants outstanding | 195,000 | |||||||||||||||||||||||
Warrant Holder 2 [Member] | Warrant 6 [Member] | Professional Services 2 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 2 | |||||||||||||||||||||||
Warrants outstanding | 75,000 | |||||||||||||||||||||||
Warrant Holder 2 [Member] | Warrant 7 [Member] | Professional Services 2 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 2 | |||||||||||||||||||||||
Warrants outstanding | 25,000 | |||||||||||||||||||||||
Warrant Holder 3 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 0 | 0 | ||||||||||||||||||||||
Warrant Holder 3 [Member] | Services To Be Provided [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 1 | $ 1 | ||||||||||||||||||||||
Warrants outstanding | 600,000 | 10,000 | 115,000 | |||||||||||||||||||||
Warrant Holder 4 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 0 | 0 | ||||||||||||||||||||||
Warrant exercise price | $ 1 | |||||||||||||||||||||||
Warrants outstanding | 300,000 | |||||||||||||||||||||||
Warrant transferred | 300,000 | 300,000 | ||||||||||||||||||||||
Warrant Holder 5 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 375,000 | 375,000 | ||||||||||||||||||||||
Warrant transferred | 175,000 | 175,000 | ||||||||||||||||||||||
Warrant Holder 5 [Member] | Exercise Price $1.00 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 175,000 | 175,000 | ||||||||||||||||||||||
Warrant Holder 5 [Member] | Warrant 1 [Member] | Professional Services 1 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 1.50 | |||||||||||||||||||||||
Warrants outstanding | 200,000 | |||||||||||||||||||||||
Warrant Holder 9 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 0 | 0 | ||||||||||||||||||||||
Warrant transferred | 200,000 | |||||||||||||||||||||||
Warrant Holder 9 [Member] | Warrant 1 [Member] | Professional Services 1 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 1.50 | |||||||||||||||||||||||
Warrant expiration date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrants outstanding | 200,000 | |||||||||||||||||||||||
Warrant Holder 6 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 250,000 | 250,000 | ||||||||||||||||||||||
Warrant Holder 6 [Member] | Debt Extension [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 1.50 | |||||||||||||||||||||||
Warrant expiration date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrants outstanding | 250,000 | |||||||||||||||||||||||
Warrant Holder 7 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 400,000 | 400,000 | ||||||||||||||||||||||
Warrant Holder 7 [Member] | Warrant [Member] | Debt Extension [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 1.50 | |||||||||||||||||||||||
Warrant expiration date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrants outstanding | 400,000 | |||||||||||||||||||||||
Warrant Holder 8 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 0 | 0 | ||||||||||||||||||||||
Warrant Holder 8 [Member] | Warrant [Member] | Professional Services [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 1.50 | $ 1.50 | ||||||||||||||||||||||
Warrant expiration date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrants outstanding | 775,000 | 775,000 | ||||||||||||||||||||||
Warrant Holder 10 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 0 | 0 | ||||||||||||||||||||||
Warrant Holder 10 [Member] | Warrant 2 [Member] | Professional Services 2 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 1.50 | |||||||||||||||||||||||
Warrant expiration date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrants outstanding | 246,666 | 350,000 | ||||||||||||||||||||||
Warrant Holder 10 [Member] | Warrant [Member] | Professional Services 2 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 1.50 | $ 1.50 | $ 1.50 | |||||||||||||||||||||
Warrants outstanding | 50,000 | 53,334 | ||||||||||||||||||||||
Warrant Holder 11 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 470,000 | 470,000 | ||||||||||||||||||||||
Warrant Holder 11 [Member] | Exercise price $2.00 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 150,000 | 150,000 | ||||||||||||||||||||||
Warrant Holder 11 [Member] | Exercise Price $1.00 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 150,000 | 150,000 | ||||||||||||||||||||||
Warrant Holder 11 [Member] | Warrant 3 [Member] | Professional Services 3 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 1.50 | $ 1 | ||||||||||||||||||||||
Warrant expiration date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrants outstanding | 170,000 | 150,000 | ||||||||||||||||||||||
Warrant Holder 11 [Member] | Warrant 3b [Member] | Professional Services 3 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 2 | |||||||||||||||||||||||
Warrants outstanding | 150,000 | |||||||||||||||||||||||
Warrant Holder 12 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 0 | 0 | ||||||||||||||||||||||
Warrant Holder 12 [Member] | Warrant 4 [Member] | Professional Services 4 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 1.50 | $ 1.50 | $ 1.50 | |||||||||||||||||||||
Warrant expiration date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrants outstanding | 918,050 | 100,000 | 1,018,050 | |||||||||||||||||||||
Warrant Holder 13 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 0 | 0 | ||||||||||||||||||||||
Warrant Holder 13 [Member] | Warrant 5 [Member] | Professional Services 5 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 1.50 | $ 1.50 | $ 1.50 | |||||||||||||||||||||
Warrant expiration date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrants outstanding | 210,000 | 15,000 | 225,000 | |||||||||||||||||||||
Warrant Holder 14 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 0 | 0 | ||||||||||||||||||||||
Warrant Holder 14 [Member] | Warrant 6 [Member] | Professional Services 6 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 1 | $ 1 | ||||||||||||||||||||||
Warrant expiration date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrants outstanding | 100,000 | 100,000 | ||||||||||||||||||||||
Warrant Holder 15 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 0 | 0 | ||||||||||||||||||||||
Warrant Holder 15 [Member] | Warrant 7 [Member] | Professional Services 7 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 1.50 | $ 1.50 | ||||||||||||||||||||||
Warrant expiration date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrants outstanding | 100,000 | 100,000 | ||||||||||||||||||||||
Warrant Holder 16 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 0 | 0 | ||||||||||||||||||||||
Warrant Holder 16 [Member] | Warrant 8 [Member] | Professional Services 8 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 1.50 | $ 1.50 | $ 1.50 | |||||||||||||||||||||
Warrant expiration date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrants outstanding | 75,000 | 25,000 | 100,000 | |||||||||||||||||||||
Warrant Holder 17 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 0 | 0 | ||||||||||||||||||||||
Warrant Holder 17 [Member] | Warrant 9 [Member] | Professional Services 9 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 1.50 | $ 1.50 | ||||||||||||||||||||||
Warrant expiration date | Jan. 31, 2024 | |||||||||||||||||||||||
Warrants outstanding | 52,050 | 52,050 | ||||||||||||||||||||||
Warrant Holder 18 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 250,000 | 250,000 | ||||||||||||||||||||||
Warrant Holder 18 [Member] | Investment [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 3 | |||||||||||||||||||||||
Warrant expiration date | Mar. 30, 2024 | |||||||||||||||||||||||
Warrants outstanding | 250,000 | |||||||||||||||||||||||
Warrant Holder 19 [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrants outstanding | 0 | 0 | ||||||||||||||||||||||
Warrant Holder 19 [Member] | Professional Services [Member] | ||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||
Warrant exercise price | $ 1.50 | $ 1.50 | ||||||||||||||||||||||
Warrant expiration date | Apr. 01, 2027 | |||||||||||||||||||||||
Warrants outstanding | 300,000 | 300,000 |
COMMITMENTS AND CONTINGENCIES_2
COMMITMENTS AND CONTINGENCIES (Details) | Sep. 30, 2022 USD ($) |
Commitments and Contingencies Disclosure [Abstract] | |
2022 (remaining) | $ 11,250 |
2023 | 45,000 |
2024 | 14,999 |
Total minimum lease payments: | 71,249 |
Less amount representing interest | (5,074) |
Present value of minimum lease payments: | $ 66,175 |
COMMITMENTS AND CONTINGENCIES_3
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Aug. 31, 2022 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | Jun. 30, 2021 | |
Product Liability Contingency [Line Items] | |||||||
Operating lease expense | $ 11,250 | $ 11,250 | $ 33,750 | $ 33,750 | |||
Operating Lease, Right-of-Use Asset | 68,541 | 68,541 | $ 17,925 | ||||
Operating Lease, Liability, Current | 9,834 | 9,834 | 14,724 | ||||
Operating Lease, Liability, Noncurrent | 56,341 | 56,341 | 0 | ||||
Minimum future royalty payments | 0 | 0 | 0 | ||||
Other Income | 0 | 0 | 0 | 77,500 | |||
Non-refundable fee | $ 75,000 | ||||||
Initial license fee | 75,000 | ||||||
Minimum [Member] | |||||||
Product Liability Contingency [Line Items] | |||||||
Maintenance fees | 15,000 | ||||||
Maximum [Member] | |||||||
Product Liability Contingency [Line Items] | |||||||
Maintenance fees | $ 25,000 | ||||||
Pharmaceutical Marketing Partner [Member] | |||||||
Product Liability Contingency [Line Items] | |||||||
Deferred Revenue | $ 1,000,000 | ||||||
Other Income | $ 1,000,000 | ||||||
Royalty advances | $ 0 | $ 0 | $ 0 | $ 0 |
401(k) PROFIT-SHARING PLAN (Det
401(k) PROFIT-SHARING PLAN (Details Narrative) - USD ($) | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Retirement Benefits [Abstract] | ||
Employer contributions | $ 0 | $ 0 |
INCOME TAXES (Details Narrative
INCOME TAXES (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Income Tax Disclosure [Abstract] | ||||
Income Tax Expense (Benefit) | $ 0 | $ 0 | $ 0 | $ 0 |